research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Type-2 Immunity Associated With Type-1 Related Skin Inflammatory Diseases: Friend Or Foe?
Type-2 immunity may influence skin diseases and could be targeted for treatment.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Apremilast and Tofacitinib Exert Differential Effects in the Humanized Mouse Model of Alopecia Areata
Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.
research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
research Alopecia Areata: Medical Treatments
Some treatments for autoimmune hair loss work, but JAK inhibitors like tofacitinib are promising for regrowth.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
research A Retrospective Review of Pediatric Alopecia Areata Cases Seen in a Tertiary Institution in Singapore
Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.
research Baricitinib in Pediatric Chronic Immune Thrombocytopenia and Associated Autoimmune Conditions: A Case Report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research Continued Treatment With Baricitinib Results in Meaningful Scalp Responses Among Scalp Non-Responder Patients With Eyebrow/Eyelash Regrowth in the First Year
Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.
research Diagnosis And Management Of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.
research Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs
Current treatments for Alopecia Areata have mixed success, and there's a need for better, more accessible options and support for affected individuals.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Efficacy of Baricitinib in Patients With Different Degrees of Severe Alopecia Areata: 52-Week Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
research Markers of Venous Thromboembolism Risk in Patients with Alopecia Areata: Is There Anything to Worry About?
People with alopecia areata may have a higher risk of blood clots.
research Analyzing the Role of Tofacitinib in Treatment of Alopecia Areata: A Retrospective Analysis from a Tertiary Care Center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
research Topical SCD-153, A 4-Methyl Itaconate Prodrug, For The Treatment Of Alopecia Areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research Combination of Baricitinib and Conventional Immunomodulating Therapy for Alopecia Totalis
Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
research 66-Year-Old Female with Itchy Scalp and Hair Loss
A woman has a permanent hair loss condition treated with steroids and new medicines, but hair might not regrow.
research Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata
Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.
research Predictive Modeling of Patient Response to JAK/STAT Inhibitors and Dynamic Patient-Matching
Machine learning can predict how well patients with alopecia areata will respond to certain treatments.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis
Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.
research In-Silico Study of Bioactive Compounds of Natural Materials as a JAK-Signal Transducer and Activator of Transcription Inhibitor for Anti-Alopecia
Three compounds from Dadap leaves may help treat hair loss.